

# Jan Willem Cohen Tervaert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12032896/publications.pdf>

Version: 2024-02-01

78  
papers

9,738  
citations

87401

40  
h-index

90395

73  
g-index

79  
all docs

79  
docs citations

79  
times ranked

6041  
citing authors

#	ARTICLE	IF	CITATIONS
1	CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update. <i>Journal of Rheumatology</i> , 2021, 48, 555-566.	1.0	27
2	Avacopan for the treatment of ANCA-associated vasculitis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 717-726.	1.3	10
3	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618.	2.5	79
4	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1360-1372.	2.5	36
5	Advances in therapeutic treatment options for ANCA-associated vasculitis. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 127-136.	0.5	7
6	Should proteinase-3 and myeloperoxidase anti-neutrophil cytoplasmic antibody vasculitis be treated differently: part 2. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 384-387.	0.4	9
7	Silicone. , 2019, , 297-305.		0
8	Anti-neutrophil Cytoplasmic Antibodies (ANCA) as Disease Activity Biomarkers in a "Personalized Medicine Approach" in ANCA-Associated Vasculitis. <i>Current Rheumatology Reports</i> , 2019, 21, 76.	2.1	22
9	Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 388-394.	2.0	35
10	Autoinflammatory/autoimmunity syndrome induced by adjuvants (ASIA; Shoenfeld's syndrome): A new flame. <i>Autoimmunity Reviews</i> , 2018, 17, 1259-1264.	2.5	64
11	Seasonal Influence on the Risk of Relapse at a Rise of Antineutrophil Cytoplasmic Antibodies in Vasculitis Patients with Renal Involvement. <i>Journal of Rheumatology</i> , 2017, 44, 473-481.	1.0	18
12	Silicone breast implants and autoimmune rheumatic diseases: myth or reality. <i>Current Opinion in Rheumatology</i> , 2017, 29, 348-354.	2.0	70
13	Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1662-1668.	0.5	159
14	Chronic nasal <i>Staphylococcus aureus</i> carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate. <i>Rheumatology</i> , 2017, 56, 965-972.	0.9	53
15	Vitamin D deficiency as a risk factor for the development of autoantibodies in patients with ASIA and silicone breast implants: a cohort study and review of the literature. <i>Clinical Rheumatology</i> , 2017, 36, 981-993.	1.0	25
16	Two hundreds cases of ASIA syndrome following silicone implants: a comparative study of 30 years and a review of current literature. <i>Immunologic Research</i> , 2017, 65, 120-128.	1.3	109
17	Editorial: Can an Increase in Antineutrophil Cytoplasmic Autoantibody Titer Predict Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis?. <i>Arthritis and Rheumatology</i> , 2016, 68, 1571-1573.	2.9	13
18	HLA-DPB1 as a Risk Factor for Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 1721-1730.	2.9	44

#	ARTICLE	IF	CITATIONS
19	Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1453-1459.	0.4	56
20	Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1178-1182.	0.5	217
21	Connective tissue growth factor and the cicatrization of cellular crescents in ANCA-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1291-1299.	0.4	8
22	Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2314-2327.	3.0	167
23	The Renaissance of Antineutrophil Cytoplasmic Antibodies as a Predictor of Relapse: <i>Ippon</i> for Japan. <i>Journal of Rheumatology</i> , 2015, 42, 1734-1736.	1.0	2
24	Clinical immunology â€“ Autoimmunity in the Netherlands. <i>Immunology Letters</i> , 2014, 162, 134-140.	1.1	2
25	The <i>SEM6A6</i> Locus Is Not Associated With Granulomatosis With Polyangiïtis or Other Forms of Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitides in Europeans: Comment on the Article by Xie et al. <i>Arthritis and Rheumatology</i> , 2014, 66, 1400-1401.	2.9	13
26	DNA extraction from long-term stored urine. <i>BMC Nephrology</i> , 2013, 14, 238.	0.8	28
27	What to do when you suspect your patient suffers from pulmonary vasculitis?. <i>Expert Opinion on Medical Diagnostics</i> , 2013, 7, 1-4.	1.6	1
28	Caveolin-1 Single Nucleotide Polymorphism in Antineutrophil Cytoplasmic Antibody Associated Vasculitis. <i>PLoS ONE</i> , 2013, 8, e69022.	1.1	5
29	Antineutrophil Cytoplasmic Autoantibodies: How Are They Detected and What Is Their Use for Diagnosis, Classification and Follow-up?. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 43, 211-219.	2.9	70
30	Genetically Distinct Subsets within ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2012, 367, 214-223.	13.9	820
31	Statin-Associated Polymyalgia Rheumatica. An Analysis Using WHO Global Individual Case Safety Database: A Case/Non-Case Approach. <i>PLoS ONE</i> , 2012, 7, e41289.	1.1	27
32	Intracellular IL-10 detection in T cells by flowcytometry: The use of protein transport inhibitors revisited. <i>Journal of Immunological Methods</i> , 2012, 381, 59-65.	0.6	17
33	Hypertension: an autoimmune disease?. <i>Hypertension Research</i> , 2011, 34, 443-444.	1.5	7
34	Vitamin D-related gene expression profiles in immune cells of patients with relapsing remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2011, 235, 91-97.	1.1	21
35	Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission. <i>Journal of Neuroimmunology</i> , 2011, 239, 80-86.	1.1	157
36	Th17 expansion in MS patients is counterbalanced by an expanded CD39+ regulatory T cell population during remission but not during relapse. <i>Journal of Neuroimmunology</i> , 2011, 240-241, 97-103.	1.1	53

#	ARTICLE	IF	CITATIONS
37	Effects of vitamin D on the peripheral adaptive immune system: A review. <i>Autoimmunity Reviews</i> , 2011, 10, 733-743.	2.5	207
38	Effect of vitamin D3 supplementation on peripheral B cell differentiation and isotype switching in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1418-1423.	1.4	41
39	Rituximab in ANCA-associated vasculitis: a revolution?. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3077-3079.	0.4	16
40	New pathophysiological insights and treatment of ANCA-associated vasculitis. <i>Kidney International</i> , 2011, 79, 599-612.	2.6	131
41	Safety and T Cell Modulating Effects of High Dose Vitamin D3 Supplementation in Multiple Sclerosis. <i>PLoS ONE</i> , 2010, 5, e15235.	1.1	145
42	Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. <i>New England Journal of Medicine</i> , 2010, 363, 211-220.	13.9	1,471
43	Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010, 121, 243-246.	1.2	63
44	CD45RC Isoform Expression Identifies Functionally Distinct T Cell Subsets Differentially Distributed between Healthy Individuals and AAV Patients. <i>PLoS ONE</i> , 2009, 4, e5287.	1.1	32
45	Infectious Serologies and Autoantibodies in Wegener's Granulomatosis and Other Vasculitides. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 649-657.	1.8	43
46	EUROPLUS, ANCA BIOCHIP mosaic: PR3 and MPO antigen microdots improve the laboratory diagnostics of ANCA-associated vasculitis. <i>Journal of Immunological Methods</i> , 2009, 348, 67-73.	0.6	33
47	The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. <i>Autoimmunity Reviews</i> , 2009, 8, 621-626.	2.5	124
48	Fifty years of antineutrophil cytoplasmic antibodies (ANCA) testing: do we need to revise the international consensus statement on testing and reporting on ANCA?. <i>Apmis</i> , 2009, 117, 55-59.	0.9	21
49	Vitamin D Status Is Positively Correlated with Regulatory T Cell Function in Patients with Multiple Sclerosis. <i>PLoS ONE</i> , 2009, 4, e6635.	1.1	235
50	Hypotheses on the Etiology of Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 237-252.	2.2	94
51	Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 798-802.	0.5	99
52	TNF- $\alpha$ Bioactivity-Inhibiting Therapy in ANCA-Associated Vasculitis: Clinical and Experimental Considerations: Table 1.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1100-1107.	2.2	32
53	Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2005, 52, 2461-2469.	6.7	723
54	Autoimmunity " Vasculitis. , 2005, , 560-568.		0

#	ARTICLE	IF	CITATIONS
55	Wegener's Granulomatosis. <i>Autoimmunity</i> , 2004, 37, 313-315.	1.2	2
56	Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. <i>Arthritis and Rheumatism</i> , 2004, 51, 269-273.	6.7	123
57	Antineutrophil cytoplasmic autoantibodies and pathophysiology: new insights from animal models. <i>Current Opinion in Rheumatology</i> , 2004, 16, 4-8.	2.0	26
58	Infections and Vasculitis. , 2004, , 549-557.		0
59	Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. <i>Kidney International</i> , 2003, 63, 670-677.	2.6	132
60	A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. <i>New England Journal of Medicine</i> , 2003, 349, 36-44.	13.9	1,239
61	ANCA Testing in Monitoring the Activity of the Disease. <i>Kidney and Blood Pressure Research</i> , 2003, 26, 226-230.	0.9	4
62	Staphylococcus aureus and Wegener's granulomatosis. <i>Arthritis Research</i> , 2002, 4, 77.	2.0	112
63	Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease. <i>Journal of Clinical Immunology</i> , 2002, 22, 281-288.	2.0	61
64	ARE ANTINEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIDES PAUCI-IMMUNE?. <i>Rheumatic Disease Clinics of North America</i> , 2001, 27, 833-848.	0.8	36
65	Antineutrophil cytoplasmic antibodies to proteinase 3 in Wegener's granulomatosis: Epitope analysis using synthetic peptides. <i>Kidney International</i> , 2001, 59, 147-159.	2.6	42
66	Is Wegener's granulomatosis an autoimmune disease?. <i>Current Opinion in Rheumatology</i> , 2000, 12, 3-10.	2.0	53
67	Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. <i>Kidney International</i> , 2000, 57, 2195-2206.	2.6	192
68	Differential B- and T-cell activation in Wegener's granulomatosis. <i>Journal of Allergy and Clinical Immunology</i> , 1999, 103, 885-894.	1.5	179
69	The role of superantigens in vasculitis. <i>Current Opinion in Rheumatology</i> , 1999, 11, 24-33.	2.0	79
70	Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. <i>Kidney International</i> , 1998, 53, 253-263.	2.6	89
71	Pulmonary Manifestations of Systemic Vasculitides. , 1998, , 53-85.		2
72	Specificity, pathogenecity, and clinical value of antiendothelialcell antibodies. <i>Seminars in Arthritis and Rheumatism</i> , 1997, 27, 98-109.	1.6	73

#	ARTICLE	IF	CITATIONS
73	Trimethoprimâ€“Sulfamethoxazole (Co-Trimoxazole) for the Prevention of Relapses of Wegener's Granulomatosis. <i>New England Journal of Medicine</i> , 1996, 335, 16-20.	13.9	754
74	Neutrophil activation in vitro and in vivo in Wegener's granulomatosis. <i>Kidney International</i> , 1994, 45, 1120-1131.	2.6	177
75	NEUROLOGIC MANIFESTATIONS OF SYSTEMIC VASCULITIDES. <i>Rheumatic Disease Clinics of North America</i> , 1993, 19, 913-940.	0.8	37
76	Antineutrophil cytoplasmic antibodies: A still-growing class of autoantibodies in inflammatory disorders. <i>American Journal of Medicine</i> , 1992, 93, 675-682.	0.6	220
77	Detection of autoantibodies against myeloid lysosomal enzymes: A useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. <i>American Journal of Medicine</i> , 1991, 91, 59-66.	0.6	140
78	Maintaining remission in patients with granulomatosis with polyangiitis or microscopic polyangiitis: the role of ANCA. <i>Expert Opinion on Orphan Drugs</i> , 0, , 1-12.	0.5	4